Staar Surgical Co (STAA) — Analysis Summary
Staar Surgical Co (STAA) has a market cap of $1.36B with year-over-year revenue growth of -23.7%. Net margin stands at -33.6%. The stock trades at a P/E ratio of -64.7.
Key Takeaways
- Revenue changed -23.7% year-over-year
- Net margin of -33.6%
- P/E ratio of -64.7
Compared to other companies in the OPHTHALMIC GOODS sector, STAA posted revenue growth of -23.7% and trades at a P/E of -64.7.
Staar Surgical Co (STAA)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
The latest filing shows negative free cash flow.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Sector
OPHTHALMIC GOODS
Employees
957
Headquarters
MONROVIA, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.